EUR 115.88 For Business Accounts Only

MorphoSys AG (MOR) - Financial Analysis Review

MorphoSys AG (MOR) - Financial Analysis Review

Summary

MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product include MOR208, MOR202, MOR103, MOR209/ES414, MOR106, and MOR107, among others. It drugs are used in the treatment of different types of cancer, psoriasis, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, solid tumors, eye disease, and other inflammatory diseases.

GlobalData's MorphoSys AG (MOR) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

MorphoSys AG Key Recent Developments:

Jan 05,2017: Dr. Malte Peters to become new Chief Development Officer of MorphoSys
Nov 07,2016: MorphoSys Reports Results for the First Nine Months of 2016
Sep 19,2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSyss Dutch Lanthipeptide Subsidiary
Sep 12,2016: MorphoSys Appoints Four R&D Experts to its Newly Formed Scientific Advisory Board
Aug 01,2016: MorphoSys Reports Results for the First Six Months of 2016


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.